GALT - Galectin Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.3800
-0.0100 (-0.29%)
At close: 4:00PM EDT

3.3800 0.00 (0.00%)
After hours: 4:41PM EDT

Stock chart is not supported by your current browser
Previous Close3.3900
Open3.4900
Bid3.3700 x 1000
Ask3.4400 x 800
Day's Range3.3300 - 3.4700
52 Week Range3.1600 - 6.9800
Volume197,076
Avg. Volume344,919
Market Cap191.414M
Beta (3Y Monthly)3.58
PE Ratio (TTM)N/A
EPS (TTM)-0.4180
Earnings DateNov 11, 2019 - Nov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2019. Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “Over the past several months we have made significant progress advancing our proprietary compound, belapectin (GR-MD-02) for a Phase 3 trial. After having raised approximately $44.9 million in our Rights Offering and selecting a leading global CRO with deep experience in our therapeutic area and operations in over 60 countries as our clinical research organization (CRO), we recently submitted our Phase 3 clinical trial protocols to the FDA for comment along with a draft Phase 4 synopsis and statistical analysis plan.

  • Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View
    Zacks

    Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

    Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

  • Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
    Zacks

    Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y

    Endo (ENDP) beats on both sales and earnings in the second quarter of 2019. However, both metrics decline year over year due to weak generic business.

  • Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
    Zacks

    Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance

    Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.

  • GlobeNewswire

    Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for assessment the Phase 3 protocol for using belapectin (GR-MD-02) for the treatment of compensated non-alcoholic steatohepatitis (NASH) cirrhosis without esophageal varices (the NASH-RX trial).

  • GlobeNewswire

    Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise

    The Rights Offering resulted in the issuance of approximately 10.4 million shares of the Company’s common stock at a price of $4.28 per share, for total gross proceeds of $44.5 million to the Company. Investors in the Rights Offering also received warrants for the purchase of approximately 2.6 million shares of the Company’s common stock with an exercise price of $7.00 per share, which expire seven years after issuance. After giving effect to the rights offering, the Company has approximately 56 million shares of common stock issued and outstanding.

  • What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)?
    Simply Wall St.

    What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)?

    The big shareholder groups in Galectin Therapeutics, Inc. (NASDAQ:GALT) have power over the company. Institutions...

  • GlobeNewswire

    Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price (i.e., the final computed price) of the common stock and related warrant subscribed in its Rights Offering, which expired on May 23, 2019 at 5:00 p.m. Eastern Time. In the Rights Offering, the Company gave each common stockholder and certain warrant holders the right to buy units, each consisting of 0.3 shares of common stock and a warrant for 0.075 shares of Company common stock. The subscription price for each share of common stock in the offering and the related warrant is the lesser of the Initial Price of $5.50 per share of common stock or the Alternate Price. As specified in the prospectus, the Alternate Price is determined by multiplying 95 percent of the volume-weighted average price of the Company’s common stock for the 25-day trading period from April 18, 2019 through May 23, 2019, which has now been determined to be $4.28 per share.

  • GlobeNewswire

    Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019

    On April 15th the Company announced the record date, closing date and pricing of the rights offering.  I wanted to share my thoughts about the offering and our rationale for the pricing.  Also, I felt I should describe, from my perspective, how the offering will work. As I have previously expressed, in advocating for the rights offering to the board as our first option, my sole intention was to limit dilution to you, my co-investors.  The board and management agreed with me that a rights offering is the most democratic method of raising money.  While there are many different financing options, I wanted to pick the one that I believe favors the existing stockholders. Simply put, at this point in our history, we need to fund our Phase-3 clinical trial in patients with NASH cirrhosis.  Not many companies are fortunate enough to advance a new drug compound this far.  Today we are well advanced into the trial design, and we are looking forward to getting the trial underway.  For that I want to thank our team led by our CEO, Harold Shlevin, and our employees and researchers.  I am a long-term investor who clearly believes in the Company but joining the board has given me a new degree of respect and understanding of the complexity involved in the clinical trial process.  I am extremely grateful to all involved.

  • GlobeNewswire

    Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2019. Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “The past quarter we continued to prepare for a Phase 3 clinical trial program with our proprietary compound, belapectin (formerly known as GR-MD-02), the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis without esophageal varices.

  • GlobeNewswire

    Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key dates and pricing structure for its previously announced rights offering of approximately 14 million shares of its common stock and approximately 3.5 million warrants to purchase common stock. The Company intends to issue non-transferable subscription rights to purchase shares of its common stock and warrants to common stockholders and certain warrant holders as of 5:00 p.m. Eastern Time on Monday, April 29, 2019 (the “Record Date”). Investors who do not currently own common stock of Galectin Therapeutics and who wish to participate in the Rights Offering may purchase shares in the market so long as those purchases settle prior to the Record Date.

  • GlobeNewswire

    Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

    NORCROSS, Ga., April 02, 2019 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold.

  • GlobeNewswire

    Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

    Providence Cancer Institute and Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination immunotherapy for cancer using GR-MD-02, to be given at a workshop for Recent Advances in Drugging the Innate Immune Response, on Monday, March 25, at 15:00 MDT, at Grays Peak at the Keystone Symposia on Molecular and Cellular Biology in Keystone, Colorado. Elizabeth Sturgill, Ph.D., Postdoctoral Fellow in the laboratory of Associate Member William L. Redmond, Ph.D., at the Earle A. Chiles Research Institute in Portland, Oregon, a division of Providence Cancer Institute, will give an oral presentation entitled “Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival.” The session will focus on the effects GR-MD-02 has had when combined with various T-cell targeting immunotherapies, including both aOX40 and Pembrolizumab (KEYTRUDA®).

  • Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%
    Simply Wall St.

    Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy sharesRead More...

  • GlobeNewswire

    Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders

    As you may know, I have been on the board for slightly over a year and Chairman since May 2018.  While my message relates primarily to the Company’s Rights Offering that was announced today, I also thought it was important to share some of my other thoughts about the Company. Before I speak about anything else, I would like to categorically state that I believe in free market capitalism and its inherent power to improve and save lives.  No other system has proven to possess this ability, and in fact other systems tend to yield the opposite result.  My belief in the power of free market capitalism extends from technical innovation to transparency in most aspects of society.  I intend to cover both aspects as they relate to Galectin Therapeutics.

  • GlobeNewswire

    Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration Statement on Form S-3 with the U.S. Securities and Exchange Commission (“SEC”) (available at www.sec.gov) with regards to a planned Rights Offering of common stock and warrants to its stockholders. In the Rights Offering the Company will seek to raise between $50 million and $70 million. Richard E. Uihlein, chairman of the board, has indicated his non-binding intent to purchase $20 million in the offering.

  • GlobeNewswire

    Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2018. Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “Over the last year we have been positioning the company to undertake a Phase 3 clinical trial -- the NASH-RX trial -- with our proprietary compound GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis without esophageal varices.

  • GlobeNewswire

    Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Galectin Therapeutics to Present at Berenberg NASH Day in New York

    NORCROSS, Ga., Feb. 25, 2019 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold.

  • Conatus (CNAT) Completes Enrollment in Phase II NASH Study
    Zacks

    Conatus (CNAT) Completes Enrollment in Phase II NASH Study

    Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.

  • Ascendis Pharma Files IND for Hypoparathyroidism Candidate
    Zacks

    Ascendis Pharma Files IND for Hypoparathyroidism Candidate

    Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.

  • Alkermes Sinks as FDA Refuses to Approve Depression Drug
    Zacks

    Alkermes Sinks as FDA Refuses to Approve Depression Drug

    Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

  • AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
    Zacks

    AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA

    AVEO Oncology (AVEO) decides against filing NDA for Fotivda on recommendation of the FDA. The agency remains concerned with the overall survival data.

  • Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year?

    Is (GALT) Outperforming Other Medical Stocks This Year?

  • GlobeNewswire

    Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure

    Galectin Therapeutics Inc. (GALT), the leading developer of therapeutics that target galectin proteins, today announced that its largest institutional shareholder, 10X Fund L.P., has converted all of its Series B Convertible Preferred Stock into Common Stock of Galectin Therapeutics. All special voting rights and protective provisions that previously benefited the Series B Preferred Stock were extinguished by the conversion to Common Stock (see footnote 5 of our financial statements included in our Annual Report on Form 10-K for 2017 for all of the now extinguished special voting rights and protective provisions).